PNEUMOVAX™ 23
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pneumococcal Infection
Conditions
Pneumococcal Infection
Trial Timeline
Oct 31, 2014 → Apr 9, 2015
NCT ID
NCT02260882About PNEUMOVAX™ 23
PNEUMOVAX™ 23 is a approved stage product being developed by Merck for Pneumococcal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT02260882. Target conditions include Pneumococcal Infection.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02260882 | Approved | Completed |
| NCT01734239 | Phase 3 | Completed |
Competing Products
20 competing products in Pneumococcal Infection